Table 1. Transduction of adult human BM... | American Society of Hematology

Table 1.

Transduction of adult human BM cells capable of repopulating NOD/SCID-β₂M^−/− mice

No. of cells per mouse^*	% of human cells^†			% GFP⁺ human cells^‡
No. of cells per mouse^*	CD45/71⁺	CD19/20⁺/34⁻	CD15⁺	CD45/71⁺	CD19/20⁺/34⁻	CD15⁺
26 000	0.6	0.2	0.04	25	31	31
33 000	5.0	0.5	1.5	16	28	22
33 000	3.8	1.0	0.8	24	17	31
33 000	2.5	0.4	0.7	32	14	37
33 000	7.4	0.7	2.1	18	13	21

No. of cells per mouse^*	% of human cells^†			% GFP⁺ human cells^‡
No. of cells per mouse^*	CD45/71⁺	CD19/20⁺/34⁻	CD15⁺	CD45/71⁺	CD19/20⁺/34⁻	CD15⁺
26 000	0.6	0.2	0.04	25	31	31
33 000	5.0	0.5	1.5	16	28	22
33 000	3.8	1.0	0.8	24	17	31
33 000	2.5	0.4	0.7	32	14	37
33 000	7.4	0.7	2.1	18	13	21

CD34⁺CD38⁻ cells were stimulated for 3 days with FL + SF + IL-3 + H-IL-6 and then exposed to new virus daily for 3 days. Twenty-four hours after the last addition of fresh virus, the cells were harvested and injected into sublethally irradiated NOD/SCIDβ₂M^−/− mice. These were sacrificed 6 weeks later and their marrow cells then analyzed for the presence of human cells expressing GFP as described in Materials and methods. Results are shown only for the 5 of 8 mice from 3 experiments in which engraftment of the mice with human cells was seen, where engraftment was defined as the presence of ≥ 5 lymphoid (CD34⁻CD19/20⁺) and ≥ 5 myeloid (CD15⁺) human cells per 20 000 viable cells analyzed.

This refers to the number of CD34⁺CD38⁻cells at the start of the transduction protocol, the progeny of which were injected into each NOD/SCID-β₂M^−/−mouse.

†

Values shown are the proportion of all viable (PI⁻) cells retrieved from the BM of the mice that showed reactivity with antibodies to the human cell surface antigens shown.

‡

Proportion of cells in each subpopulation of human cells indicated that were GFP⁺.

View Large

This Feature Is Available To Subscribers Only